AbbVie annual operating expenses
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Operating Expenses Growth & History (ABBV)
AbbVie's operating expenses was $27.88B for fiscal 2025.
View full AbbVie company overviewAbbVie annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27.88B | −$2.41B | −7.96% |
| 2024 | 2024-12-31 | $30.29B | $9.15B | +43.26% |
| 2023 | 2023-12-31 | $21.15B | −$1.38B | −6.11% |
| 2022 | 2022-12-31 | $22.52B | $1.70B | +8.14% |
| 2021 | 2021-12-31 | $20.83B | $1.77B | +9.31% |
| 2020 | 2020-12-31 | $19.05B | $6.21B | +48.35% |
| 2019 | 2019-12-31 | $12.84B | −$5.81B | −31.14% |
| 2018 | 2018-12-31 | $18.65B | $7.02B | +60.39% |
| 2017 | 2017-12-31 | $11.63B | $1.16B | +11.11% |
| 2016 | 2016-12-31 | $10.47B | −$356.0M | −3.29% |
| 2015 | 2015-12-31 | $10.82B | −$1.30B | −10.73% |
| 2014 | 2014-12-31 | $12.12B | $3.58B | +41.87% |
| 2013 | 2013-12-31 | $8.54B | $490.0M | +6.08% |
| 2012 | 2012-12-31 | $8.05B | −$1.13B | −12.30% |
| 2011 | 2011-12-31 | $9.19B | — | — |
AbbVie quarterly operating expenses
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.27B | $84.0M | +1.36% |
| Q1 2026 | 2026-03-31 | $6.79B | $1.19B | +21.15% |
| Q4 2025 | 2025-12-31 | $7.52B | −$4.67B | −38.32% |
| Q3 2025 | 2025-09-30 | $8.57B | $2.15B | +33.52% |
| Q2 2025 | 2025-06-30 | $6.18B | −$79.0M | −1.26% |
| Q1 2025 | 2025-03-31 | $5.61B | $190.0M | +3.51% |
| Q4 2024 | 2024-12-31 | $12.20B | $6.79B | +125.77% |
| Q3 2024 | 2024-09-30 | $6.42B | $1.26B | +24.34% |
| Q2 2024 | 2024-06-30 | $6.26B | $1.15B | +22.50% |
| Q1 2024 | 2024-03-31 | $5.42B | −$53.0M | −0.97% |
| Q4 2023 | 2023-12-31 | $5.40B | −$47.0M | −0.86% |
| Q3 2023 | 2023-09-30 | $5.16B | −$26.0M | −0.50% |
| Q2 2023 | 2023-06-30 | $5.11B | −$2.01B | −28.18% |
| Q1 2023 | 2023-03-31 | $5.47B | $702.0M | +14.72% |
| Q4 2022 | 2022-12-31 | $5.45B | −$43.0M | −0.78% |
| Q3 2022 | 2022-09-30 | $5.19B | −$459.0M | −8.13% |
| Q2 2022 | 2022-06-30 | $7.12B | $2.12B | +42.50% |
| Q1 2022 | 2022-03-31 | $4.77B | $75.0M | +1.60% |
| Q4 2021 | 2021-12-31 | $5.49B | $71.0M | +1.31% |
| Q3 2021 | 2021-09-30 | $5.65B | $1.05B | +22.82% |
| Q2 2021 | 2021-06-30 | $5.00B | −$967.0M | −16.22% |
| Q1 2021 | 2021-03-31 | $4.69B | $1.62B | +52.70% |
| Q4 2020 | 2020-12-31 | $5.42B | $2.68B | +97.70% |
| Q3 2020 | 2020-09-30 | $4.60B | $655.0M | +16.62% |
| Q2 2020 | 2020-06-30 | $5.96B | $2.93B | +96.38% |
| Q1 2020 | 2020-03-31 | $3.07B | −$50.0M | −1.60% |
| Q4 2019 | 2019-12-31 | $2.74B | −$5.98B | −68.57% |
| Q3 2019 | 2019-09-30 | $3.94B | $700.0M | +21.59% |
| Q2 2019 | 2019-06-30 | $3.04B | −$546.0M | −15.24% |
| Q1 2019 | 2019-03-31 | $3.12B | $20.0M | +0.64% |
| Q4 2018 | 2018-12-31 | $8.72B | $5.05B | +137.32% |
| Q3 2018 | 2018-09-30 | $3.24B | $557.0M | +20.74% |
| Q2 2018 | 2018-06-30 | $3.58B | $829.0M | +30.11% |
| Q1 2018 | 2018-03-31 | $3.10B | $589.0M | +23.42% |
| Q4 2017 | 2017-12-31 | $3.68B | $748.0M | +25.55% |
| Q3 2017 | 2017-09-30 | $2.69B | $118.0M | +4.60% |
| Q2 2017 | 2017-06-30 | $2.75B | $93.0M | +3.50% |
| Q1 2017 | 2017-03-31 | $2.52B | $204.0M | +8.83% |
| Q4 2016 | 2016-12-31 | $2.93B | $116.0M | +4.13% |
| Q3 2016 | 2016-09-30 | $2.57B | −$325.0M | −11.24% |
| Q2 2016 | 2016-06-30 | $2.66B | −$47.0M | −1.74% |
| Q1 2016 | 2016-03-31 | $2.31B | −$100.0M | −4.15% |
| Q4 2015 | 2015-12-31 | $2.81B | −$1.94B | −40.78% |
| Q3 2015 | 2015-09-30 | $2.89B | −$73.0M | −2.46% |
| Q2 2015 | 2015-06-30 | $2.71B | $409.0M | +17.80% |
| Q1 2015 | 2015-03-31 | $2.41B | $299.0M | +14.16% |
| Q4 2014 | 2014-12-31 | $4.75B | $2.45B | +106.97% |
| Q3 2014 | 2014-09-30 | $2.96B | $770.0M | +35.08% |
| Q2 2014 | 2014-06-30 | $2.30B | $113.0M | +5.17% |
| Q1 2014 | 2014-03-31 | $2.11B | $241.0M | +12.88% |
| Q4 2013 | 2013-12-31 | $2.29B | $174.0M | +8.21% |
| Q3 2013 | 2013-09-30 | $2.19B | $297.0M | +15.65% |
| Q2 2013 | 2013-06-30 | $2.19B | $187.0M | +9.36% |
| Q1 2013 | 2013-03-31 | $1.87B | −$168.0M | −8.24% |
| Q4 2012 | 2012-12-31 | $2.12B | — | — |
| Q3 2012 | 2012-09-30 | $1.90B | — | — |
| Q2 2012 | 2012-06-30 | $2.00B | — | — |
| Q1 2012 | 2012-03-31 | $2.04B | — | — |
AbbVie operating expenses trends
Over the last five fiscal years, AbbVie's operating expenses increased from $19.05B to $27.88B, a change of $8.83B. The latest reported quarter, Q2 2026, shows $6.27B.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
